Full-Time

Director Incentive Compensation

Updated on 5/26/2026

Deadline 5/5/27
Xeris Pharmaceuticals

Xeris Pharmaceuticals

201-500 employees

Develops ready-to-use liquid-stable injectables

Compensation Overview

$180k - $240k/yr

+ Bonus + Equity

Chicago, IL, USA

Hybrid

Minimum of three days per week in-office required.

Category
Finance & Banking (1)
Required Skills
Veeva
Forecasting
Data Analysis
Financial Modeling
Requirements
  • Bachelor’s degree in Business, Finance, Economics, or related field is required; MBA or advanced degree preferred
  • Pharmaceutical, Rare Disease and/or BioTech Industry experience
  • 10+ years of experience in incentive compensation, sales operations, finance, or related field
  • 5+ years of leadership experience with demonstrated ability to lead and develop teams
  • Deep expertise in designing and managing sales incentive compensation plans in a complex, regulated environment (pharma/biotech preferred)
  • Strong analytical and financial modeling skills with experience in data-driven decision-making
  • Experience with incentive compensation systems and data sources (e.g., IQVIA, Veeva, CRM systems, incentive compensation platforms)
  • Strong understanding of compliance and regulatory considerations in incentive compensation
Responsibilities
  • Lead the strategic design and evolution of incentive compensation plans that align with organizational goals, market dynamics, and product strategy.
  • Establish guiding principles and governance frameworks for incentive compensation across all commercial teams.
  • Evaluate plan effectiveness through performance analytics and recommend enhancements to drive productivity and ROI.
  • Partner with executive leadership to align IC strategy with revenue goals, product lifecycle stages, and go-to-market strategies.
  • Oversee end-to-end IC plan implementation, including goal setting, quota deployment, plan documentation, and payout processes.
  • Ensure accurate and timely calculation and distribution of incentive compensation payments.
  • Drive continuous improvement of IC processes, systems, and tools to enhance efficiency, scalability, and accuracy.
  • Establish and maintain standard operating procedures and documentation for all IC processes.
  • Lead advanced modeling, forecasting, and scenario analysis to evaluate plan performance and financial impact.
  • Analyze sales performance trends and incentive effectiveness to inform strategic decision-making.
  • Provide actionable insights and recommendations to Sales Leadership and executive stakeholders.
  • Ensure all incentive compensation programs comply with regulatory requirements, company policies, and industry standards.
  • Partner with Legal and Compliance to mitigate risk and maintain audit readiness.
  • Oversee documentation, approvals, and audit processes related to IC plans.
  • Serve as the primary IC subject matter expert and advisor to Sales Leadership, Finance, HR, and executive stakeholders.
  • Collaborate with HR on alignment with total rewards strategy and talent retention initiatives.
  • Partner with Finance on budgeting, accruals, and financial planning related to incentive compensation.
  • Build, lead, and develop a high-performing incentive compensation team.
  • Provide coaching, direction, and prioritization to ensure delivery of high-quality, timely work.
  • Foster a culture of accountability, continuous improvement, and collaboration
Desired Qualifications
  • MBA or advanced degree preferred
  • Pharmaceutical, Rare Disease and/or BioTech Industry experience preferred
Xeris Pharmaceuticals

Xeris Pharmaceuticals

View

Xeris Biopharma Holdings develops ready-to-use, liquid-stable injectables for serious conditions, using its XeriSol and XeriJect platforms. Their products come in prefilled syringes or devices that do not require mixing or refrigeration, enabling smaller injections and quick administration. The company differentiates itself by delivering stable, ready-to-use formulations focused on rare diseases and endocrinology, supported by a U.S.-based field force and a portfolio that includes Gvoke, Keveyis, and Recorlev. Its goal is to expand access to simple, stable injectable therapies and grow its pipeline across endocrinology, neurology, and gastroenterology through its proprietary technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • Recorlev revenue nearly doubled to $49.8 million in Q1 2026.
  • Xeris raised 2026 revenue guidance to $380 million-$390 million after strong Q1.
  • XP-8121 remains on track for Phase 3 initiation later in 2026.

What critics are saying

  • Gvoke faces Medicare coverage pressure, keeping revenue flat at $20.8 million.
  • Recorlev faces generic litigation threats from two applicants targeting March 2040 patents.
  • XP-8121 remains pre-Phase 3, leaving Xeris dependent on current marketed products.

What makes Xeris Pharmaceuticals unique

  • Xeris builds ready-to-use liquid-stable injectables through XeriSol and XeriJect.
  • Gvoke replaces multi-step glucagon mixing with pre-filled syringe and auto-injector options.
  • Recorlev and Keveyis target rare endocrine and neuromuscular diseases with limited competition.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Xeris Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

2%
Living Vision International Ministries
May 7th, 2026
Xeris Biopharma: Q1 earnings snapshot.

Xeris Biopharma: Q1 earnings snapshot. CHICAGO (AP) - CHICAGO (AP) - Xeris Biopharma Holdings, Inc. (XERS) on Thursday reported first-quarter net income of $2.2 million. On a per-share basis, the Chicago-based company said it had profit of 1 cent. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was breakeven on a per-share basis. The company posted revenue of $83.1 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $80 million. Xeris Biopharma expects full-year revenue in the range of $380 million to $390 million. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XERS at https://www.zacks.com/ap/XERS

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma achieves profitability with $60M adjusted EBITDA, eyes 30% growth in 2026

Xeris Biopharma achieved financial self-sustainability in 2025, reporting its first full year of net income and nearly $60 million in adjusted EBITDA. The company posted 44% revenue growth, driven by its three commercial products, with Recorlev nearly doubling its patient base to approximately 700 patients. For 2026, Xeris has issued revenue guidance of $375 million to $390 million, representing over 30% growth. The company plans to initiate a Phase III trial for XP-8121 in the second half of 2026, requiring a $25 million increase in R&D spending. Xeris filed patent infringement lawsuits against two generic drug applicants to protect Recorlev patents extending to March 2040. Management maintains peak sales expectations of $1 billion for Recorlev by 2035 and $1 billion to $3 billion for XP-8121.

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma beats Q4 estimates with $85.8M revenue, forecasts up to $390M for 2025

Chicago-based Xeris Biopharma Holdings reported fourth-quarter earnings of $11.1 million, or 6 cents per share, surpassing Wall Street expectations of 3 cents per share. Revenue reached $85.8 million, exceeding analyst forecasts of $81.4 million. For the full year, the company reported profit of $554,000 with revenue of $291.8 million. Xeris Biopharma expects full-year revenue between $375 million and $390 million. The results beat expectations across all metrics surveyed by Zacks Investment Research.

Association of Diabetes Care and Education Specialists
Aug 10th, 2025
ADCES names Katelyn O'Brien 2026 Diabetes Care and Education Specialist of the Year

I wish to extend my gratitude to those that nominated me, the ADCES Awards Committee, and Xeris Pharmaceuticals for their continued support for this award.

BioSpace
Mar 31st, 2025
Xeris Announces Changes to Its Board of Directors

The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy.